In the evening of April 19 John and Amber Guthro received an alarming phone call concerning their five-year-old son, Jack.
“I guess because of the joint pain we thought he might have arthritis, but he also had a rash so we were not really sure what was going on. We just knew that they sounded really urgent,” said Amber Guthro.
Joint pain, a nasty rash on his cheeks, and a level of lethargy that would concern any parent of a preschooler, were all symptoms that caused them to reach out to their family doctor.
ImmuPharma PLC (LON:IMM) is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by High unmet medical need,Low marketing costs and Relatively low development costs